Dr. Katy Rezvani

MD Anderson Cancer Center, Houston, Texas, USA

Dr. Katy Rezvani, Professor of Medicine at the MD Anderson Cancer Center of the University of Texas, is the Chairman of Kiadis Pharma’s Independent Data Monitoring Committee for its multicenter Phase II clinical trial for ATIR101.

Dr. Robert Preti

PCT (Progenitor Cell Therapy)

Dr. Robert “Bob” Preti is Chief Scientific Officer of Neostem and President of Neostem’s subsidiary, PCT. He is one of the most renowned and experienced people in developing cellular therapeutics and is closely involved in the development of the manufacturing process for ATIR™ through consulting and development services provided by PCT.